ISSN 1662-4009 (online)

Previous issue | Volume 18 | ESPEYB18 | Next issue

Yearbook of Paediatric Endocrinology 2021

8. Adrenals

Important for Clinical Practice

ey0018.8-3 | Important for Clinical Practice | ESPEYB18

8.3. Modified-release hydrocortisone in congenital adrenal hyperplasia

DP Merke , A Mallappa , W Arlt , A Brac de la Perriere , A Linden Hirschberg , A Juul , J Newell-Price , CG Perry , A Prete , DA Rees , N Reisch , N Stikkelbroeck , P Touraine , K Maltby , FP Treasure , J Porter , RJ Ross

J Clin Endocrinol Metab 2021; 106(5): e2063–e2077. authors report the findings of a 6-month, randomized, phase 3 trial, with a single arm extension, to investigate the efficacy, safety and tolerability of modified release hydrocortisone (MC-HC) replacement therapy versus standard glucocorticoid replacement therapy in 122 adult patients with c...

ey0018.8-4 | Important for Clinical Practice | ESPEYB18

8.4. Urinary GC-MS steroid metabotyping in treated children with congenital adrenal hyperplasia

C Kamrath , MF Hartmann , J Pons-Kuhnemann , SA Wudy

Metabolism. 2020; 112: 154354. order to better define treatment groups and improve treatment monitoring, the authors performed a retrospective metabotyping analysis using 24-h GC–MS urinary steroid metabolome measurements in young prepubertal children (n=109; age 7.0–1.6 years) with classical congenital adrenal hyperplasia (CAH) ...

ey0018.8-5 | Important for Clinical Practice | ESPEYB18

8.5. Improved urinary cortisol metabolome in addison disease: A prospective trial of dual-release hydrocortisone

S Espiard , J McQueen , M Sherlock , O Ragnarsson , R Bergthorsdottir , P Burman , P Dahlqvist , B Ekman , BE Engstrom , S Skrtic , J Wahlberg , PM Stewart , G Johannsson

J Clin Endocrinol Metab 2021; 106(3):814–825., the authors performed a randomized, 12-week, crossover study in order to assess cortisol metabolism during dual-release hydrocortisone (DR-HC) and conventional hydrocortisone (TID-HC) therapy in patients with primary adrenal insufficiency (n=50). Healthy controls (n=124) were i...

ey0018.8-6 | Important for Clinical Practice | ESPEYB18

8.6. Reproductive and perinatal outcomes in women with congenital adrenal hyperplasia: A population-based cohort study

AL Hirschberg , S Gidlof , H Falhammar , L Frisen , C Almqvist , A Nordenskjold , A Nordenstrom

J Clin Endocrinol Metab. 2021; 106(2): e957–e965. authors investigated the reproductive and perinatal outcomes in women with congenital adrenal hyperplasia (CAH) compared with control women in the largest such population-based study to date. Women with CAH had lower birth rates, were more likely to develop gestational diabetes, and had other ...

ey0018.8-7 | Important for Clinical Practice | ESPEYB18

8.7. Targeted metabolomics as a tool in discriminating endocrine from primary hypertension

Z Erlic , P Reel , S Reel , L Amar , A Pecori , CK Larsen , M Tetti , C Pamporaki , C Prehn , J Adamski , A Prejbisz , F Ceccato , C Scaroni , M Kroiss , MC Dennedy , J Deinum , K Langton , P Mulatero , M Reincke , L Lenzini , AP Gimenez-Roqueplo , G Assie , A Blanchard , MC Zennaro , E Jefferson , F Beuschlein

J Clin Endocrinol Metab. 2021 Mar 25;106(4):1111–1128. this multicentre patient cohort study, the authors investigated the use of targeted metabolomics to discriminate primary hypertension (PHT) from endocrine forms of hypertension (EHT). They identified 16 metabolites that help to discriminate between PHT and EHT.Arteri...